It can be hard for drug makers to pull the plug on a drug in development, even when all signs indicate they should – resulting in many drugs getting past the preclinical floodgates, only to fail. The mistake: Not having a clinical strategy from the get-go.

A smart, defined clinical strategy sets objective expectations at the beginning of a drug’s development for when and on what criteria development will be terminated. This forces drug developers to ask, “Why are we creating this drug in the first place?”

The answer—and the true drug development opportunity—lies in an understanding of the best available science and patient target(s) for the drug.

Before you take your drug to the point of no return, learn more about TD2’s insight from president and CEO, Stephen Gately, on how to be more strategic from the start in Applied Clinical Trials.

Probiotics in focus: How does L. reuteri affect gut health?

The composition of our intestinal microbiota, may be a measure of our overall health. The presence of an imbalance in the microbial gut community is...

Read more +

CAR T-cell Program Development: Key Considerations

For decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, these treatments are not always...

Read more +

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +

GET STARTED

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.

Skip to content